PA
RDY icon

Profund Advisors’s Dr. Reddy's Laboratories RDY Stock Holding History

Profund Advisors’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201K Buy
13,891
+960
+7% +$13K 0.01% 1089
2026
Q1 		$179K Sell
12,931
-1,418
-10% -$19.7K 0.01% 1042
2025
Q4 		$201K Sell
14,349
-956
-6% -$13.4K 0.01% 1168
2025
Q3 		$214K Buy
15,305
+1,026
+7% +$14.8K 0.01% 943
2025
Q2 		$215K Buy
14,279
+1,773
+14% +$25.3K 0.01% 860
2025
Q1 		$165K Buy
12,506
+1,964
+19% +$27.1K 0.01% 923
2024
Q4 		$166K Sell
10,542
-26,343
-71% -$396K 0.01% 1036
2024
Q3 		$586K Sell
36,885
-4,105
-10% -$66.1K 0.02% 468
2024
Q2 		$625K Buy
40,990
+2,225
+6% +$31.9K 0.02% 425
2024
Q1 		$569K Buy
38,765
+60
+0.2% +$876 0.02% 530
2023
Q4 		$539K Buy
+38,705
New +$517K 0.02% 490
2022
Q3 		– Sell
-19,230
Closed -$213K – 1000
2022
Q2 		$213K Buy
+19,230
New +$209K 0.01% 877
2019
Q4 		– Sell
-54,810
Closed -$415K – 1313
2019
Q3 		$415K Sell
54,810
-6,025
-10% -$44.8K 0.02% 697
2019
Q2 		$456K Sell
60,835
-13,525
-18% -$106K 0.02% 674
2019
Q1 		$602K Buy
74,360
+16,265
+28% +$124K 0.03% 552
2018
Q4 		$438K Sell
58,095
-24,780
-30% -$174K 0.03% 534
2018
Q3 		$573K Sell
82,875
-7,800
-9% -$52.1K 0.02% 701
2018
Q2 		$584K Sell
90,675
-10,725
-11% -$67.7K 0.02% 679
2018
Q1 		$663K Sell
101,400
-9,750
-9% -$68.3K 0.03% 618
2017
Q4 		$835K Buy
111,150
+39,810
+56% +$287K 0.03% 546
2017
Q3 		$509K Buy
71,340
+12,180
+21% +$87.6K 0.02% 752
2017
Q2 		$499K Buy
59,160
+2,900
+5% +$23.6K 0.02% 742
2017
Q1 		$452K Sell
56,260
-580
-1% -$5.01K 0.02% 917
2016
Q4 		$515K Sell
56,840
-6,080
-10% -$56.6K 0.02% 879
2016
Q3 		$584K Sell
62,920
-3,240
-5% -$30.9K 0.03% 674
2016
Q2 		$678K Sell
66,160
-9,190
-12% -$84.2K 0.03% 597
2016
Q1 		$681K Buy
+75,350
New +$674K 0.04% 550
2013
Q4 		– Sell
-149,575
Closed -$1.13M – 1712
2013
Q3 		$1.13M Buy
149,575
+6,755
+5% +$49.1K 0.06% 366
2013
Q2 		$1.08M Buy
+142,820
New +$1.04M 0.08% 253

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Profund Advisors's RDY Position: Q2 2026 in Review

Profund Advisors increased its Dr. Reddy's Laboratories (RDY) stake by 7.4% in Q2 2026, buying an estimated $13K and bringing the position to 13,891 shares worth $201K. The position accounts for 0.01% of the portfolio, ranked #1089.

Profund Advisors first reported a position in RDY in Q2 2013 and has held it in 29 quarters since. The position peaked at $1.13M in Q3 2013. 238 funds tracked by Wall St. Rank hold RDY as of Q2 2026.

  • Profund Advisors held 13,891 shares of Dr. Reddy's Laboratories worth $201K as of Q2 2026.
  • Profund Advisors bought 960 Dr. Reddy's Laboratories shares in Q2 2026, an estimated $13K.
  • Dr. Reddy's Laboratories made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #1089 holding.
  • Profund Advisors first reported a position in Dr. Reddy's Laboratories in Q2 2013 and has held it in 29 quarters since.
  • Profund Advisors's Dr. Reddy's Laboratories position peaked at $1.13M in Q3 2013.
  • 238 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.